In the Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) study, which included 764 CKD patients with type 2 diabetes and albuminuria [167], the study participants were randomly assigned to receive either finerenone or a placebo. Here, NR3C2 is linked to chronic kidney disease.